slt

Grant Spindler

Global Head of Operations

Experience and Expertise

Grant has more than 20 years of experience in the pharmaceuticals/medical device industry. He has a proven ability to shepherd products from the R&D stage to commercial viability in highly regulated environments on a global scale.

Since joining Sirtex in 2007 as Global Technical Manager at the company's headquarters in Sydney, Grant has displayed a mastery of international operations. After serving two-year stints as Global Manufacturing Manager in Singapore and Boston, he accepted the same role back in Sydney. He assumed his current position as Global Head of Operations in 2018.

Before joining Sirtex, Grant was Head of Cyclotron Operations for the Australian Nuclear Science & Technology (ANSTO) organization. He began at ANSTO in 1999 as Production Manager for Australian Radiopharmaceuticals and Industrials.

Grant holds a Master of Business Administration in Technology from the Australian Graduate School of Management (AGSM) along with a Bachelor of Applied Science in Chemistry from the University of Technology in Sydney.




slt
Kevin R. Smith
CEO

slt
Paul Andreassi
Executive Vice President of Global Quality Assurance

slt
Jesse Hansen
Global Head of Marketing

slt
Francis Jannot
Executive Vice President of International Sales

slt
Cathleen Lowndes
Chief Human Resources Officer

slt
Amy Pan
Chief Financial Officer

slt
Suki Shergill
Executive Vice President, Global Pricing & Market Access

slt
Kevin P. Smith
General Counsel & Executive Vice President, Business Development

slt
Grant Spindler
Global Head of Operations

slt
MaryLou Stroumbos
Executive Vice President, Regulatory Affairs

slt
Mark Turco
Global Chief Medical Officer & Executive Vice President of Research & Development



Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

Effective May 7, 2021, SIR-Spheres will have the following indication for use:
SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

Click here to view our Technical Bulletin.

Ok